Parasite | Eso | Sto | Cancer | ESD
[¾Öµ¶ÀÚ Áõ·Ê ÆíÁö 7]
[2015-11-5. ¾Öµ¶ÀÚ ÆíÁö]
±³¼ö´Ô ¾È³çÇϼ̽À´Ï±î? XXXÀÔ´Ï´Ù. ¸»¾¸Çϼ̴ø ¿ø°í¸¦ ½áº¸¾Ò½À´Ï´Ù.
¼Ò°³Çϱ⠺βô·¯¿ï Á¤µµÀÇ ¹ÌõÇÑ °æÇèÀÌÁö¸¸ ¿¾³¯ Á¦ÀÚ±îÁö ¿¬¶ôÁּż ì°ÜÁÖ½Ã´Ï È²¼ÛÇÒ µû¸§ÀÔ´Ï´Ù.Áö±ØÈ÷ °³ÀÎÀûÀÎ °æÇèÀ» Çü½Ä¾øÀÌ ½áº¸¾Ò½À´Ï´Ù. Çй®ÀûÀÎ °¡Ä¡´Â º°·Î ¾øÁö¸¸ Àϵ¶ÇØÁÖ½Ã¸é °¨»çÇÏ°Ú½À´Ï´Ù.
°³¿øÇÏ°í 4´Þ¸¸¿¡ ÀÖ¾ú´ø ÀÏÀÔ´Ï´Ù. 70´ë ¿©ÀÚ È¯ÀÚÀÔ´Ï´Ù. ¿ÀÈÄ 7½Ã Áø·á°¡ ³¡³ª¼ Åð±ÙÇÏ·Á°í Áغñ Áß '°¡½¿ÀÌ ´ä´äÇÏ°í üÇÑ °Í °°´Ù'´Â Áõ»óÀ¸·Î º´¿øÀ¸·Î µé¾î¿À¼Ì°í ±¸¿ª°¨ÀÌ ½ÉÇϼ̴ÂÁö ºñ´ÒºÀÁö¿¡ ¿¬½Å ±¸Å並 ÇÏ°í °è¼Ì½À´Ï´Ù. °³¿øÇÏ°í ÀÖÀ¸¸é °¡Àå ¸¹ÀÌ µè°Ô µÇ´Â Chief Complaint Áß Çϳª°¡ 'üÇÑ °Í °°´Ù'ÀÔ´Ï´Ù. ¾È»öÀÌ Ã¢¹éÇÏ°í ±×³É ÀÇ»ç·Î¼ÀÇ °¨ÀÌ ¾ÈÁÁ¾Æ º°´Ù¸¥ ÁøÂû¾øÀÌ ¹Ù·Î ½ÉÀüµµºÎÅÍ È®ÀÎÇÏ¿´°í anterior lead¿¡ ST-elevation ¹× limb lead reciprocal change°¡ °üÂûµÇ´Â STEMI¿´½À´Ï´Ù.
±Ùó ´ëÇк´¿ø coronary team hotline ¹øÈ£¸¦ ¾Ë°í ÀÖ¾î ¹Ù·Î ´çÁ÷ ±³¼ö´Ô°ú ÅëÈÇÑ ÈÄ ¸¶Ä§ Åð±Ù½Ã°£ÀÌ¾î¼ Á¦Â÷·Î ÀÀ±Þ½Ç·Î ¸ð¼Å´Ù µå·È½À´Ï´Ù. Ãâ¹ßÇÏ¸é¼ º¸È£ÀÚ¿¡°Ô ¿¬¶ôÇÏ¿© º´¿ø ÀÀ±Þ½Ç·Î ¿À½Ã¶ó°í ÇÏ¿´°í ÀÀ±Þ½Ç¿¡¼ ÁغñÇÏ°í ÀÖ´ø ¼øȯ±â ³»°ú ´çÁ÷ ¼±»ý´Ô²² ¾ÈÀüÇÏ°Ô ÀΰèÇÏ¿´½À´Ï´Ù. Door to needle time 30ºÐ ¾ÈÂÊÀ̾ú´ø °ÍÀ¸·Î ±â¾ïÇÕ´Ï´Ù. PCI ½ÃÇà ÈÄ ÈÄÀ¯Áõ ¾øÀÌ ¿ÏÀüÈ÷ ȸº¹Çϼ̽À´Ï´Ù. 2ÁÖ ÈÄ °¡Á·µéÀÌ ÄÉÀÍÀ» »çµé°í ¿Í¼ °í¸¿´Ù°í ÀλçÇÏ°í °¡¼Ì°í ¿Â°¡Á·ÀÌ ÀúÈñ º´¿ø ´Ü°ñÀÌ µÇ¾ú½À´Ï´Ù.
¿ì¸®³ª¶ó¿¡¼ °³ÀÎÀÇ¿øÀº ¿¹¾àÁ¦°¡ ¾Æ´Ñ ¾ÆÇÁ¸é ¾ðÁ¦µçÁö °¥ ¼ö ÀÖ´Â °÷ÀÌ¾î¼ ÀÀ±Þ½Ç·Î °¡¾ßÇÒ È¯ÀÚµéÀÌ ²Ï ¸¹ÀÌ °ÅÄ¡°Ô µË´Ï´Ù. ±×·Î ÀÎÇؼ Áø·á¿¡ ´ëÇÑ riskµµ ºÐ¸í ´õ Ŭ ¼ö ¹Û¿¡ ¾ø°í Ç×»ó ±äÀåÇؼ ȯÀÚ¸¦ º¾´Ï´Ù. °³¿ø ÈÄ ¾Æħ¸¶´Ù '¿À´Ãµµ ¹«»çÈ÷ ÇϷ縦 Àß º¸³¾ ¼ö ÀÖ°Ô ÇØ ÁֽʽÿÀ'¶ó°í ±âµµÇÏ¸é¼ Ãâ±ÙÇÕ´Ï´Ù. ¾î¶² Ä£±¸´Â '°³¿øÀÇÀÇ »î°ú °³ÀÎÅýà ±â»çÀÇ »îÀÌ ºñ½ÁÇÏ´Ù'°í À̾߱â ÇÕ´Ï´Ù. Ç×»ó ¸¶À½ Á¹À̸ç ÀÏÇÑ´Ù´Â °Í°ú ±×³¯ ¸ÅÃâ¿¡ ÀÏÈñÀϺñÇÑ´Ù´Â ºñ½ÁÇÑ Á¡ÀÌ ÀÖ½À´Ï´Ù.
°³¿øÇغ¸¸é üÇß´Ù´Â ÁÖ¼Ò°¡ Âü ¸¹½À´Ï´Ù. ´Ü¼øÇÑ Àå¿°À̳ª FDºÎÅÍ AMI±îÁö ¸»ÀÔ´Ï´Ù. Ç×»ó ȯÀÚ¿¡°Ô "'üÇß´Ù'´Â °ÍÀº '¹è°¡ ¾ÆÇÁ´Ù' °°Àº Áõ»óÀÌÁö Áø´ÜÀÌ ¾Æ´Ï¸ç üÇÑ Áõ»óÀ» À¯¹ßÇÏ´Â º´Àº ¸Å¿ì ¸¹À¸¸ç, Áø´ÜÀÌ Á¤È®ÇØ¾ß Ä¡·á°¡ Á¦´ë·Î µË´Ï´Ù" ¶ó°í ¼³¸íÇÏÁö¸¸ ¿©ÀüÈ÷ Àß ¸ø ¾Ë¾ÆµéÀ¸½Ã´Â ºÐµéÀÌ ¸¹½À´Ï´Ù. ¿ö³« Á¶»ó ´ë´ë·Î »Ñ¸®±íÀº ÇÑÀÇÇÐÀûÀÎ °ü³äÀÌ ÀÚ¸®Àâ°í Àֱ⠶§¹®ÀÏ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. "¿Ö ¿øÀå´ÔÀº üÇÑ °É °¡Áö°í Àå¿°À̶ó°í ÇϽʴϱî?" ¿äÁòµµ ¸¹ÀÌ µè´Â ÀÌÀ̱âÀÔ´Ï´Ù. ±×·¡¼ ¾î¶² ¿øÀå´ÔµéÀº ±×³É "üÇϼ̳׿ä" ¶ó°í ÇÏ¸é¼ ´«³ôÀÌ¿¡ ¸ÂÃá Áø·á¸¦ ÇÑ´Ù°í ÇÕ´Ï´Ù. ±×·¯³ª Àú´Â ¿À´Ãµµ ¿½ÉÈ÷ ±×°Ô ¾Æ´Ï¶ó°í ¼³¸íÇÏ°í ÀÖ½À´Ï´Ù.
[2015-11-5. ÀÌÁØÇà ´äÀå]
³Ê¹« ÈǸ¢ÇÑ ÀÏÀ» Çϼ̽À´Ï´Ù. Å« ¹Ú¼ö¸¦ º¸³À´Ï´Ù. ¦¦¦.
50´ë ¿©ÀÚÀÔ´Ï´Ù. ¸¸¼ºÀûÀÎ °¡·¡, ±âħÀ¸·Î °í»ýÇÏ´ø ºÐÀ¸·Î Ÿ¿ø¿¡¼ ¸¸¼º ±â°üÁö¿°°ú ±â°üÁö È®ÀåÁõÀ¸·Î Áø´Ü¹Þ°í ¼ö³âµ¿¾È ´ëÁõÄ¡·á³ª Áõ»ó ¾ÇȽà Ç×»ýÁ¦ Ä¡·á¸¦ ¹ÞÀ¸¸ç Áö³»´ø ºÐÀÔ´Ï´Ù. ½ÉÇØÁø °¡·¡ ±âħÀ¸·Î ³»¿øÇϼ̰í ÈäºÎ ¹æ»ç¼± °Ë»ç»ó ÀüÇüÀûÀÎ NTM nodular brochiectatic formÀÌ º¸¿© È£Èí±â ³»°ú °í¿øÁß ±³¼ö´Ô²² ÀÇ·ÚÇÏ¿´°í NTMÀ¸·Î È®ÁøµÇ¾î Ä¡·á¹Þ°í ÇöÀç´Â Áõ»óÀÌ °ÅÀÇ ¾ø¾îÁ³½À´Ï´Ù. Àü°øÀÇ ½ÃÀý °í¿øÁß ±³¼ö´Ô²² ¼ö½ÊÂ÷·Ê µé¾ú´ø NTM °ÀÇ°¡ °³¿øÇؼ ÀÌ·¸°Ô µµ¿òÀÌ µÇ¾ú½À´Ï´Ù.
[2015-11-22. °í¿øÁß ±³¼ö´Ô ´äÀå]
ÃÖ±Ù ¹Ì±¹°ú ¸¶Âù°¡Áö·Î ±¹³»¿¡¼µµ ºñ°áÇÙÇ×»ê±Õ(nontuberculous mycobacteria, NTM) ÆóÁúȯ ȯÀÚ°¡ °è¼Ó Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. NTM ÆóÁúȯÀº °áÇÙ±Õ°ú °°Àº Ç×»ê±Õ(acid fast bacilli, AFB)À¸·Î AFB µµ¸»°Ë»ç¿¡¼ ¾ç¼ºÀ» º¸¿© Æó°áÇÙÀ¸·Î ¿ÀÁøµÇ´Â ÀÏÀÌ ÈçÇÕ´Ï´Ù. NTM ÆóÁúȯÀÇ °¡Àå ÈçÇÑ 2°¡Áö ÇüÅ´ (1) Æó°áÇÙ°ú ¸¶Âù°¡Áö·Î ÆóÀÇ »ó¿±¿¡ °øµ¿À» µ¿¹ÝÇÑ »ó¿±°øµ¿Çü(upper lobe cavitary form)°ú (2) ÆóÀÇ ¿ìÁß¿±°ú ÁÂ»ó¿± ¼³»óºÐÀý(lingular segment)¿¡ ±â°üÁöÈ®ÀåÁõ°ú ´Ù¹ß¼º °áÀýÀ» µ¿¹ÝÇÏ´Â °áÀý ±â°üÁöÈ®ÀåÁõÇü(nodular bronchiectatic form)ÀÔ´Ï´Ù. °áÀý ±â°üÁöÈ®ÀåÁõÇüÀÇ NTM ÆóÁúȯÀº ÁÖ·Î 50´ë ÀÌ»óÀÇ ¿©¼º¿¡¼ ¹ß»ýÇÕ´Ï´Ù.
ȯÀÚºÐÀº 50´ë ¿©¼ºÀ¸·Î º´·Â¿¡¼ ¼ö³â ÀÌ»ó Áö¼ÓµÇ´Â ±âħ°ú °¡·¡ ±×¸®°í °£ÇæÀûÀÎ °´Ç÷·Î ±Þ¼º ÆóÁúȯÀÌ ¾Æ´Ñ ¸¸¼º È£Èí±âÁúȯÀÌ Àǽɵ˴ϴÙ. ÈäºÎ¿¢½º·¹ÀÌÀÌ¿¡¼´Â ¾çÃø »ó¿±Àº Á¤»óÀÌ°í, ½ÉÀåÀÇ ¾çÃø ¿ìÁß¿±°ú ÁÂ»ó¿± ¼³»óºÐÀý¿¡ ±â°üÁöÈ®ÀåÁõÀÌ ÀǽɵǴ °ø±âÀ½¿µ°ú ±× ÁÖÀ§ ±â°üÁöÆó·Å(bronchopneumonia)°¡ ÀǽɵǴ À½¿µÀÌ °üÂûµË´Ï´Ù. ÀÓ»ó»ó°ú ÈäºÎ¿¢½º·¹ÀÌ ¼Ò°ß¸¸À¸·Îµµ °¡Àå ÀǽɵǴ ÁúȯÀº NTM ÆóÁúȯÀ̶ó°í ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÈäºÎ CT ¼Ò°ßÀ» º¸¸é ÈäºÎ¿¢½º·¹ÀÌ ¼Ò°ßÀÌ ´õ Àß ÀÌÇØµÇ½Ç °Ì´Ï´Ù.
ȯÀÚ´Â °´´ã AFB µµ¸»°ú ¹è¾ç°Ë»ç¸¦ 3ȸ ½ÃÇàÇÏ¿´°í, ¸ðµÎ NTMÀÌ ¹è¾çµÇ¾úÀ¸¸ç ±Õµ¿Á¤°Ë»ç¿¡¼ Mycobacterium massiliense¶ó°í ÇÏ´Â ¸Å¿ì µå¹® NTMÀ¸·Î È®ÀεǾú½À´Ï´Ù. NTM ÆóÁúȯÀº °¢°¢ÀÇ ¿øÀαտ¡ µû¶ó Ç×»ýÁ¦ Ä¡·á°¡ ´Ù¸£¸ç, M. massiliense¿Í °°Àº µå¹® ¿øÀαÕÀº Ç¥ÁØÈµÈ Ç×»ýÁ¦ Ä¡·á¹æ¹ýÀÌ Á¤¸³µÇ¾î ÀÖÁö ¾Ê½À´Ï´Ù. ´ÙÇàÈ÷µµ ¿øÀαÕÀÌ Ç×»ýÁ¦ ³»¼ºÀÌ ¾ø¾î Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀÀÌ ÁÁ¾Æ 1³â ÀÌ»ó Ç×»ýÁ¦ Ä¡·á ÈÄ Áõ»óÀÌ ¸¹ÀÌ È£ÀüµÇ¾ú½À´Ï´Ù.
[2015-11-5. ÀÌÁØÇà ´äÀå]
°í¿øÁß ±³¼ö´ÔÀÇ Á¦°¡ ¸Å¿ì Á¸°æÇÏ´Â ¼±¹è´ÔÀ̽ʴϴÙ. TrainingÀº Àúº¸´Ù ´Ê°Ô ¹ÞÀ¸¼ÌÁö¸¸... ¹®µæ ¸î ³â Àü NTM ȯÀÚ¿¡¼ reflux esophagitis°¡ ¸¹´Ù´Â ¿¬±¸¸¦ ÇÔ²²ÇÏ¿© chest Áö¿¡ ¹ßÇ¥ÇÑ ±â¾ïÀÌ ³³´Ï´Ù (Koh. Chest 2007). ÀÌ ¿¬±¸ÇÏ´À¶ó NTM ȯÀÚ ³»½Ã°æÀ» Âü ¸¹ÀÌ Çß½À´Ï´Ù.
Prevalence of gastroesophageal reflux disease in patients with nontuberculous mycobacterial lung disease.
BACKGROUND: Knowledge of the relationship between respiratory disorders and gastroesophageal reflux disease (GERD) is increasing. However, the association between GERD and pulmonary disease caused by nontuberculous mycobacteria (NTM) has not been studied in detail. We investigated the prevalence of GERD in patients with the nodular bronchiectatic form of NTM lung disease.
METHODS: Fifty-eight patients with the nodular bronchiectatic form of NTM lung disease underwent ambulatory 24-h esophageal pH monitoring. Of the 58 patients, 27 patients were identified as having Mycobacterium avium complex infection (15 with Mycobacterium intracellulare and 12 with M avium), and 31 patients had Mycobacterium abscessus pulmonary infection.
RESULTS: The prevalence of GERD in patients with the nodular bronchiectatic form of NTM lung disease was 26% (15 of 58 patients). Only 27% (4 of 15 patients) had typical GERD symptoms. No statistically significant differences were found between patients with GERD and those without GERD with regard to age, sex, body mass index, or pulmonary function test results. However, patients with GERD were more likely to have a sputum smear that was positive for acid-fast bacilli (12 of 15 patients, 80%), compared with patients without GERD (19 of 43 patients, 44%) [p = 0.033]. In addition, bronchiectasis and bronchiolitis were observed in more lobes in patients with GERD than in patients without GERD (p = 0.008 and p = 0.005, respectively).
CONCLUSIONS: Patients with the nodular bronchiectatic form of NTM lung disease have a high prevalence of increased esophageal acid exposure, usually without typical GERD symptoms.
[2015-12-18] ¹Ú»ó¾ð µ¿¹®²²¼ °í¿øÁß ±³¼ö´Ô²² ÀÇ·ÚÇÏ¿´´ø ȯÀÚ »ç·Ê¸¦ ÆÄÆ®³ÊÁî ¼¾ÅÍ¿¡¼ Áö¸éÀ¸·Î ¼Ò°³ÇÏ¿´½À´Ï´Ù.
40´ë ³²ÀÚÀÔ´Ï´Ù. 4³â ÀÌ»ó ¸¸¼º º¹ÅëÀ¸·Î ¿©·¯ º´¿ø¿¡¼ ¸¹Àº °Ë»ç¸¦ ¹Þ¾ÒÀ¸³ª Ưº°ÇÑ Áø´ÜÀ» ¹ÞÁö ¸øÇϼ̽À´Ï´Ù. »ç½Ç '¿À·¡µÈ Áõ»ó¿¡´Ù ´ëÇк´¿ø¿¡¼µµ Áø´ÜµÇÁö ¾Ê´Â º´À» Á¦°¡ ÁøÂû ÇѹøÀ¸·Î Áø´ÜÇϱâ´Â ¾î·Á¿ï °Í °°´Ù'°í »ý°¢Çß½À´Ï´Ù. ÀÚ¼¼È÷ º´·Â ûÃ븦 Çغ¸´Ï ÃÖ±Ù ¼ö°³¿ù°£ üÁßÀÌ 3-4kg °¨¼ÒÇÏ¿´°í, ½Ä»ç¸¦ ÇÏ°í ÀÏÁ¤ÇÑ ½Ã°£ÀÌ Áö³ª¸é Ç×»ó ÅëÁõÀÌ ¹ß»ýÇϸç, °¡²û ¹«¾ð°¡ º¹ºÎ¿¡¼ ¿òÁ÷ÀÌ´Â °ÍÀÌ ´À²¸Áø´Ù°í Çß½À´Ï´Ù. ´Ü¼ø º¹ºÎ »çÁø»ó ¿ìÇϺ¹ºÎ¿¡ small bowel loop°¡ ´Ã¾î³ ¼Ò°ßÀÌ °üÂûµÇ¾ú°í Ç÷¾×°Ë»ç »ó CRP°¡ 2.1·Î Áõ°¡µÇ¾î ÀÖ¾ú½À´Ï´Ù. ÀüÇüÀûÀÎ ¼ÒÀå Å©·Ðº´À¸·Î ÆÇ´ÜµÇ¾î ±è¿µÈ£ ±³¼ö´Ô²² ÀÇ·ÚÇÏ¿´½À´Ï´Ù. ÇöÀç ȯÀÚ´Â À¯ÁöÄ¡·áÇÏ¸é¼ Áõ»óÀÌ ¸ðµÎ ¼Ò½ÇµÇ¾î Àß Áö³»°í ÀÖ½À´Ï´Ù.
¹°·Ð ÀúÇÑÅ× ¿ÔÀ» ¶§ ¾î´À Á¤µµ Áõ»óÀÌ ¸íÇÐÇØÁø »óÅ¿´±â ¶§¹®¿¡ Áø´ÜÀÌ µÇ¾ú°ÚÁö¸¸ ȯÀÚ´Â ¼ö³âµ¿¾È Áø´ÜµÇÁö ¾Ê´ø ±«·Î¿î º´À» Áø´ÜÇØÁØ °í¸¶¿î ÀÇ»ç·Î »ý°¢ÇÏ°í ÀÖ½À´Ï´Ù. ¸¸¼º º¹ÅëÀº Ç×»ó IBD¸¦ °¨º°Áø´Ü¿¡ ³Ö¾î¾ß ÇÏ´Â °Í °°½À´Ï´Ù. ±×¸®°í ´Ü¼ø º¹ºÎ »çÁøµµ º¹ÅëÀÇ °¨º°¿¡ ²Ï À¯¿ëÇÒ °æ¿ì°¡ ÀÖ½À´Ï´Ù. SRC (Samsung Referral Center)¸¦ ÅëÇØ º¹ºÎ CT¸¦ È®ÀÎÇÒ ¼ö ÀÖ¾ú´Âµ¥ distal jejunum°ú ileum Àüü¸¦ involveÇÏ´Â transmural wall thickeningÀÌ °üÂûµÇ°í Èĺ¹º®ÀÇ reactive lymphadenopathy°¡ °üÂûµÇ¾î ¼ÒÀå Å©·Ðº´¿¡ ÇÕ´çÇÑ ¼Ò°ßÀ̾ú½À´Ï´Ù.
13¼¼ ³²ÀÚÀÔ´Ï´Ù. ¼ö³â°£ÀÇ ¼³»ç ¹× ÇϺ¹ºÎ ºÒÆí°¨À» È£¼ÒÇÏ´ø ÁßÇлýÀÔ´Ï´Ù. Ÿ¿ø¿¡¼ °ú¹Î¼º´ëÀåÁõÈıº(IBS-D)À¸·Î ¿©·¯ Â÷·Ê Áø´ÜÇÏ¿´°í Ưº°ÇÑ Ä¡·á ¾øÀÌ Áö³»°í ÀÖ¾ú½À´Ï´Ù. ÃÖ±Ù¿¡´Â ¼³»ç°¡ ½ÉÇØ Áö»çÁ¦ ¿øÇÏ¸ç ³»¿øÇÏ¿´½À´Ï´Ù, ÀÚ¼¼ÇÑ º´·Â ûÃë»ó ÃÖ±Ù¿¡ üÁßÀÌ Àß ´ÃÁö ¾Ê°í °£ÇæÀûÀÎ Ç÷º¯ÀÌ ÀÖ¾ú´Âµ¥ Ä¡Áú ¶§¹®ÀÏ °ÍÀ̶ó°í »ý°¢ÇÏ°í ÀÖ¾ú½À´Ï´Ù. IBD ÀǽÉÇÏ°í ³»½Ã°æ °Ë»ç»ó UC pancolitis·Î ±è¿µÈ£ ±³¼ö´Ô²² ÀÇ·ÚÇÏ¿´°í ÇöÀç À¯ÁöÄ¡·á ÇÏ¸é¼ °ÅÀÇ Áõ»ó ¾øÀÌ Àß Áö³»°í ÀÖ½À´Ï´Ù.
½ºÅ©¸®´× ´ëÀå ³»½Ã°æ¿¡¼ ´ëÀå ¿ëÁ¾À» Á¦°ÅÇߴµ¥ ÀÛÀº Å©±âÀÓ¿¡µµ ºÒ±¸ÇÏ°í Á¡¸·¾ÏÀ¸·Î ³ª¿Ô´ø Áõ·ÊµéÀÔ´Ï´Ù. ¸ðµÎ ¿ÏÀüÀýÁ¦µÇ¾î¼ Ãß°¡ ¼ö¼ú¾øÀÌ °æ°ú °üÂû ÁßÀÎ ºÐÀÔ´Ï´Ù. ¼ö·Ã¹ÞÀ» ¶§ À嵿°æ ±³¼ö´ÔÀÌ °Á¶ÇϽôø °Íó·³ lobulating contour¸¦ °¡Áø ¿ëÁ¾Àº Á¶½ÉÇؼ ÀýÁ¦ÇØ¾ß ÇÒ °Í °°½À´Ï´Ù. ½ÇÁ¦ Á¡¸·¾ÏÀÎ °æ¿ì°¡ ¸¹½À´Ï´Ù.
60´ë ³²ÀÚÀÔ´Ï´Ù. °£ÇæÀûÀÎ ÁÂÇϺ¹ºÎ ºÒÆí°¨À¸·Î ³»¿øÇϼ̽À´Ï´Ù. º¹ÁÂÇϺ¹ºÎ ÅëÁõÀº ´ëÀåÀÌ ¿øÀÎÀÏ °¡´É¼ºÀÌ ¸¹±â ¶§¹®¿¡ ÀþÀº ȯÀÚÀÇ °æ¿ì º¯ºñ°¡ ÀÖ´ÂÁö ³ëÀκеéÀÎ °æ¿ì ´ëÀå ³»½Ã°æÀ» Çغ¸¼Ì´ÂÁö È®ÀÎÇÕ´Ï´Ù. ´ëÀå³»½Ã°æ °æÇèÀº ¾ø¾ú°í üÁß°¨¼Ò³ª Ç÷º¯, º¯ºñ µîÀÇ Áõ»óÀº ¾øÀ¸¼Ì½À´Ï´Ù.´ëÀå³»½Ã°æ¿¡¼ S-colon AV 20cm °¡·®¿¡ LST°¡ °üÂûµÇ¾ú½À´Ï´Ù. Á¶Á÷°Ë»ç °á°ú adenocarcinoma well differentiated·Î È®ÀεǾî SMC ¿Ü°ú·Î ¼ö¼ú ÀÇ·Úµå·È°í Á¡¸·¾ÏÀ¸·Î È®ÀÎµÇ¾î º¹°°æ ¼ö¼ú ÈÄ ¿ÏÄ¡µÇ¾ú½À´Ï´Ù.
°ø´Ü °ËÁø ³»½Ã°æ¿¡¼ À§¾ÏÀ» Áø´ÜÇÏ¿´°í ¼ö¼úº¸³Â´ø Áõ·ÊµéÀÔ´Ï´Ù.
50´ë ¿©ÀÚ·Î ´ç´¢ ¹× °íÁöÇ÷ÁõÀ¸·Î f/u ÁßÀ̽ŠºÐÀ̾ú´Âµ¥ Ưº°ÇÑ Áõ»ó ¾øÀÌ °ø´Ü °ËÁø ³»½Ã°æ °Ë»çÈÄ ¼ö¼úÇϽŠºÐÀÔ´Ï´Ù. 1±â À§¾ÏÀ¸·Î È®ÀÎµÇ¾î ¼ö¼ú·Î Ä¡·á Á¾·áµÇ¾ú°í üÁßÀÌ 10kg Á¤µµ °¨¼ÒµÇ¼Ì´Âµ¥ Ç÷¾Ð, °íÁöÇ÷Áõµµ ¸ðµÎ Á¤»óÈµÇ¾î¼ ¿äÁòÀº ¿ÀÁö ¾Ê°í °è½Ê´Ï´Ù.
70´ë ³²ÀÚ·Î ¼öÁÖ°£ ¼Ó¾²¸²ÀÌ ÀÖ¾ú´Âµ¥ °ø´Ü °ËÁø ¹ÞÀ¸·¯ ¿À¼Å¼ Á¶±âÀ§¾ÏÀ¸·Î ¼ö¼ú º¸³Â´ø Áõ·ÊÀÔ´Ï´Ù. ³ëÀκеéÀÇ ¼Ó¾²¸²Àº Àû±ØÀûÀÎ ³»½Ã°æ °Ë»ç°¡ Ç×»ó ÇÊ¿äÇÕ´Ï´Ù.
40´ë ¿©ÀڷΠƯº°ÇÑ Áõ»ó ¾øÀÌ °ø´Ü °ËÁø ½ÃÇàÇÏ¿´°í EGD»ó MB GC side¿¡ Á¶±âÀ§¾Ï( EGC type I) ÀǽɼҰßÀÌ °üÂûµÇ¾ú½À´Ï´Ù. Á¶Á÷°Ë»ç¿¡¼´Â ¼±Á¾À¸·Î È®ÀεǾú½À´Ï´Ù. ÀÌÁØÇà ±³¼ö´Ô²²¼ °Á¶ÇϽôø "À°¾ÈÀû ¼Ò°ßÀÌ Áß¿äÇÏ´Ù. ÇüÅÂÇÐÀûÀ¸·Î ¾ÏÀÌ ÀǽɵǸé Àç°ËÇϰųª ¼ö¼úÇØ¾ß ÇÑ´Ù"¶ó°í ÇÏ´Â ±³ÈÆÀÌ »ý°¢³ª ±³¼ö´Ô²² referÇÏ¿´°í ³»½Ã°æ ´Ù½Ã ÇÏ°í Á¶Á÷°Ë»ç °á°ú focal adenocarcinoma°¡ ³ª¿Ô½À´Ï´Ù.
50´ë ¿©ÀÚÀÔ´Ï´Ù. metaplastic ¹é±×¶ó¿îµå¿¡¼ À§°¢ºÎ¿¡ »ý±ä Á¶±âÀ§¾ÏÀÔ´Ï´Ù. À§°¢ºÎ¿¡ unevenÇÑ nodularity°¡ ÀÖ¾î Á¶Á÷°Ë»ç ÇÏ¿´°í À§¾ÏÀ¸·Î ³ª¿Í ±³¼ö´Ô²² ÀÇ·Ú ÈÄ ESD·Î Ä¡·áµÇ¾ú´ø Áõ·ÊÀÔ´Ï´Ù.
60´ë ¿©ÀÚÀÔ´Ï´Ù. ³»½Ã°æ °Ë»çÀÇ ¶Ç ÇϳªÀÇ Áß¿ä»çÇ× spontaneous bleeding ¼Ò°ßÀ» ±äÀåÇÏ°í ºÁ¾ß ÇÑ´Ù¿¡ ´ëÇÑ ±³ÈÆÀÌ µÇ´Â Áõ·ÊÀÔ´Ï´Ù. DiffuseÇÑ metaplastic gastritis background¿¡ ¾ÆÁÖ ¹Ì¼¼ÇÑspontaneous bleeding ¼Ò°ßÀÌ ÀÖ¾ú°í Á¶Á÷°Ë»ç °á°ú Á¶±âÀ§¾ÏÀ¸·Î È®ÀεǾú´ø Áõ·ÊÀÔ´Ï´Ù. ESD·Î Ä¡·á ÈÄ ¿ÏÄ¡µÈ »óÅÂÀÔ´Ï´Ù.
[2015-11-5. ÀÌÁØÇà ´äÀå]
¸Å¿ì ÁÁ½À´Ï´Ù. Å« ¾ÏºÎÅÍ ÀÛÀº ¾Ï±îÁö ¸¹ÀÌ ¹ß°ßÇϼ̱º¿ä. ¸î ºÐÀº Á¦°¡ Ä¡·á¸¦ Çß´ø °Í °°½À´Ï´Ù. ȯÀÚ¸¦ ¿½ÉÈ÷ ÁøÂûÇÏ°í Áß¿äÇÑ º´À» ¹ß°ßÇÏ¿© ÀûÀýÇÑ ½ÃÁ¡¿¡ ÀÇ·ÚÇØ Áּż °¨»çÇÕ´Ï´Ù.
´ëÀå¾ÏÀ¸·Î ¼ö¼ú º¸³Â´ø Áõ·ÊµéÀÔ´Ï´Ù.
70´ë ¿©ÀÚ·Î °³¿øÇÏ°í óÀ½ Áø´ÜÇß´ø ¾ÏÀÔ´Ï´Ù. Ç÷º¯ ¹× Àܺ¯°¨À¸·Î ³»¿øÇϽźÐÀ¸·Î rectal cancer multiple meta·Î ¼ö¼ú ÈÄ Ç×¾ÏÄ¡·áÇϽô٠1³â¸¸¿¡ µ¹¾Æ°¡¼Ì½À´Ï´Ù. Ç×¾ÏÄ¡·á Áß¿¡ supportive care, ÄɸðÆ÷Æ® °ü¸®, Ç×¾ÏÁ¦ ºÎÀÛ¿ëµî¿¡ ´ëÇØ ¼º½É²¯ »ó´ãÇصå·È´õ´Ï °¡Á·µéÀÌ ¸Å¿ì °í¸¶¿ö Çϼ̽À´Ï´Ù. SMC¿¡¼ Àü°øÀÇ·Î ÀÏÇÒ¶§ Ç÷¾×Á¾¾ç³»°ú¿¡¼ supportive care ¿½ÉÈ÷ ÇÏ¸ç ½×Àº °æÇèÀÌ °³¿øÇؼµµ µµ¿òÀÌ µÇ¾ú½À´Ï´Ù.
80´ë ¿©ÀÚ·Î Ç÷º¯À¸·Î ³»¿øÇϼ̽À´Ï´Ù. Á¦°¡ Á¶±âÀ§¾ÏÀ» Áø´ÜÇß´ø ȯÀÚÀÇ ¾î¸Ó´ÏÀ̽ʴϴÙ. Á÷Àå¾Ï Áø´ÜÇÏ°í SMC¿¡¼ ¼ö¼úÈÄ Á¶±âÁ÷Àå¾ÏÀ¸·Î ¿ÏÄ¡µÇ¼Ì½À´Ï´Ù. "ÇÑ°¡Á· Áß 2¸íÀ» Á¶±â¾ÏÀ¸·Î Áø´ÜÇؼ ¿ì¸®³ª¶ó ÃÖ°íº´¿øÀÎ »ï¼ºº´¿ø¿¡ ±³¼ö´Ô²² Á÷Á¢ ¿¬¶ôÇؼ(SRC¿¡ ¿¬¶ôÇѰǵ¥) ¼ö¼ú±îÁö Àâ¾ÆÁÖ°í ¼ö¼úÀÌ ÀßµÇ¾î¼ ¿ÏÄ¡±îÁö µÇ¾ú´Ù." ÀÌÂë µÇ¸é °¡Á·µéÀÌ µ¿³×¿¡¼ ¸íÀǶó°í ¼Ò¹®³»°í ´Ù´Õ´Ï´Ù. ÀúÈñ º´¿ø ÆòÆÇÀÌ ¾öû ÁÁ¾ÆÁø °è±â°¡ µÇ¾ú½À´Ï´Ù. °³¿øÀº ÀÌ·± ¾à°£ÀÇ ¿îµµ µû¶óÁà¾ß ÇÕ´Ï´Ù.
50´ë ¿©ÀÚ·Î 2´ÞÀüºÎÅÍ ½ÃÀÛµÈ Àܺ¯°¨ ¹× ¹èº¯ ½À°ü º¯È·Î ´ëÀå ³»½Ã°æ °Ë»ç»ó Á÷Àå¾ÏÀ¸·Î Áø´ÜµÇ¾ú´ø Áõ·ÊÀÔ´Ï´Ù. ¼ö¼úÈÄ º´±â´Â pT3N2M0 ¿´½À´Ï´Ù.
Áõ·Ê 17 Pernicious anema + atrophic gastritis
40´ë ¿©ÀÚÀÔ´Ï´Ù. Pernicious anemia(Vit B12 deficiency megaloblastic anemia)·Î ´ëÇк´¿ø ÀÇ·Ú·Î Á¤±âÀûÀ¸·Î ÀúÈñ º´¿ø¿¡¼ vitamin B12 injectionÀ» ¹ÞÀ¸½Ã´Â ºÐÀÔ´Ï´Ù. ¼ÒȺҷ® Áõ»óÀÌ ¿À·¡µÇ¾î À§³»½Ã°æÀ» º¼ ±âȸ°¡ ÀÖ¾ú´Âµ¥ ¿ì¸®³ª¶ó¿¡ ÈçÇÏÁö ¾ÊÀº diffuse corporal atrophic gastritisÀÇ ÇüŸ¦ È®ÀÎÇÒ ¼ö ÀÖ¾ú½À´Ï´Ù. ÀÚ°¡¸é¿ª ±âÀü¿¡ ÀÇÇÑ parietal cell Æı«¿¡ ÀÇÇØ intrinsic factor °¨¼Ò·Î ÀÎÇÑ Vit B12 ºÎÁ·¿¡ ÀÇÇѺóÇ÷À» À¯¹ßÇÏ°Ô µÇ´Âµ¥ ±Ø´ÜÀûÀÎ Á¡¸·ÀÇ atrophy°¡ ÀλóÀûÀÔ´Ï´Ù. À§¾ÏÀÇ »ó´ëÀ§Çèµµ°¡ Áõ°¡ÇÒ ¼ö ÀÖÀ¸¹Ç·Î Á¤±â ³»½Ã°æ °Ë»ç¸¦ ±ÇÀ¯ÇÏ¿´½À´Ï´Ù.
±× ÈçÇÑ reflux esphagitis with hiatal hernia Áø´ÜÇÏ°í PPI Ä¡·á ÈÄ ¸íÀÇ°¡ µÈ Áõ·ÊÀÔ´Ï´Ù. '¼ö½Ê³â°£ ¼ÓÀÌ ºÒÆíÇؼ ¸¾ÆíÈ÷ ½Ä»ç ÇÑ ¹ø ¸øÇϼ̴Ù'¸ç °í»ýÇϽôø ºÐÀÔ´Ï´Ù. Áõ»óÀº ÇÏ·ç ¾à ÇѹøÀ¸·Î '´Ù¸¥ »îÀ» »ì°í ÀÖ´Ù'¸ç ¿À½Ç ¶§¸¶´Ù °í¸¿´Ù°í µÎ ¼Õ ²À Àâ¾ÆÁÖ°í °¡½Ê´Ï´Ù. ÇÏ·ç ¾à ÇѾËÀÌ ±× »ç¶÷ ÀÇ »îÀÇ ÁúÀ» ¹Ù²Ù´Â °æ¿ìµµ º¸°ÔµË´Ï´Ù.
[2015-11-5. ÀÌÁØÇà ´äÀå]
ù ȯÀÚ ´ÙÀ½À¸·Î °¡Àå Áß¿äÇÑ È¯ÀÚ¶ó°í »ý°¢ÇÕ´Ï´Ù. À§½Äµµ¿ª·ùÁúȯÀ¸·Î ÀÎÇÑ »îÀÇ Áú ÀúÇÏ´Â °Þ¾îº¸Áö ¾ÊÀº »ç¶÷Àº ¸ð¸¨´Ï´Ù. ¸»¾¸ÁֽŠ¹Ùó·³ ¾à ÇÑ ¾ËÀÌ ÀλýÀ» ¹Ù²ß´Ï´Ù. ±×·±µ¥ ȯÀÚµéÀÌ º´¿øÀ» ã¾Æµµ ³»½Ã°æ¿¡¼ ¶Ñ·ÇÇÑ mucosal break°¡ ¾øÀ¸¸é PPI¸¦ ¾²Áö ¸øÇÏ°Ô ÇÕ´Ï´Ù. H2 receptor antagonist ±×°Íµµ °¡Àå ¾àÇÑ cimetidine¸¸ ÀÚÀ¯·Ó°Ô ¾µ ¼ö ÀÖÀ» »ÓÀÔ´Ï´Ù. °£È¤ ranitidine, famotidineÀ» ¾²±âµµ ÇÏÁö¸¸ PPI¿¡ ºñÇؼ´Â ¾àÈ¿°¡ ºñ±³°¡ µÇÁú ¾Ê½À´Ï´Ù. Àúµµ H2RA¸¸ º¹¿ëÇϴ٠ã¾Æ¿Â GERD ȯÀÚ¿¡¼ PPI¸¦ ó¹æÇØ µå¸° ÈÄ '»ý¸íÀÇ ÀºÀÎ'À¸·Î ºÒ¸° Àûµµ ÀÖ½À´Ï´Ù. ±Ùó ÀÇ·á±â°ü¿¡¼ PPI¸¦ ¸î ¾Ë¸¸ ½á º¸¾Ò´õ¶ó¸é ½Ê³âÀÇ ¼¼¿ùÀÌ ´Þ¶óÁ³À» °ÍÀÔ´Ï´Ù. À§½Äµµ¿ª·ùÁúȯ Áõ»óÀÌ ÀÖÀ» ¶§ °Ë»ç°¡ ¾øÀ¸¸é PPI¸¦ ¾²Áö ¸øÇÏ´Â ¾ûÅ͸® Á¦µµ¸¦ ¸¸µç »ç¶÷ÀÌ µµ´ëü ´©±¸¶õ ¸»ÀԴϱî? ÁøÁ¤ ±¹¹ÎÀ» À§ÇÏ´Â °ø¹«¿øÀº ´Ù ¾îµð°¬´Ü ¸»ÀԴϱî? ¿ÀÈ£ÅëÁ¦¶ó...
Áõ·Ê 19-20 : AGE¿Í Ãʱâ Áõ»óÀÌ ºñ½ÁÇØ °Ë»ç¾øÀÌ Áø´ÜÇϱ⠱î´Ù·Î¿î Áõ·Êµé.
°³ÀÎ ÀÇ¿ø¿¡¼´Â °Ë»ç °á°ú¸¦ ¹Ù·Î È®ÀÎÇϱ⠾î·Æ½À´Ï´Ù. Ç÷¾×°Ë»ç´Â ´ÙÀ½ ³¯ È®ÀÎµÇ°í ºñ¿ëÀ̳ª ½Ã°£¶§¹®¿¡ ÃÊÀ½ÆÄ °Ë»ç¸¦ ½±°Ô ÇÒ ¼ö Àִ ȯ°æµµ ¾Æ´Õ´Ï´Ù. óÀ½ºÎÅÍ º¹ÀâÇÑ °Ë»ç¸¦ ±ÇÀ¯Çϸé ȯÀÚµéÀÌ ½È¾îÇÕ´Ï´Ù. °Ë»ç°¡ ¹Ù·Î È®Àεǰí ÇÊ¿äÇϸé CT±îÁö ÂïÀ» ¼ö ÀÖ´Â ÀÀ±Þ½Ç ȯ°æ°ú´Â ´Ù¸¨´Ï´Ù.
±×·¸Áö¸¸ ÀÀ±Þ½Ç¿¡ °¡¾ß ÇÏ´Â ÄÁµð¼ÇÀ» °¡Áø ȯÀÚµéÀÌ ¿À´Â °æ¿ìµµ ¸¹¾Æ¼ ´õ¿í °í¹ÎÀÔ´Ï´Ù. ÀÇ·áºÐÀï À§Çèµµ ÀÖ½À´Ï´Ù. Áõ»óÀÌ ½ÉÇÏÁö ¾ÊÀº °æ¿ì¿¡´Â ¹®Áø ¹× ÁøÂû ¼Ò°ß¸¸À¸·Î ÃßÁ¤Áø´ÜÀ» ÇÏ°í ¾à¹°Ä¡·á¸¦ ÇÏ¸é¼ °æ°ú °üÂûÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¹°·Ð Á¦ÀÏ ÈçÇÑ Áõ»óÀº º¹Åë, ¿, ±¸¿ª°¨, ¼³»ç µîÀÔ´Ï´Ù. AGE°¡ °¡Àå ¸¹½À´Ï´Ù¸¸ ÃʱâÁõ»óÀÌ ºñ½ÁÇؼ ¹®Áø ¹× ÁøÂû ¼Ò°ß¸¸À¸·Î °¨º°ÀÌ Àß µÇÁö ¾Ê´Â Áß¿äÇÑ ÁúȯÀÌ Liver abscess, Acute hepatitis A, perforated appendcitisÀÔ´Ï´Ù.
40´ë ¿©ÀÚÀÔ´Ï´Ù. ¿ÀÇÑ, ±ÙÀ°Åë, µÎÅë, ±¸¿ª°¨ »óº¹ºÎ ÅëÁõÀ¸·Î ³»¿øÇÏ¿´½À´Ï´Ù. óÀ½¿¡ AGE·Î Áø´ÜÇÏ°í ´ëÁõÄ¡·áÇÏ¸é¼ °æ°ú °üÂû Çϱâ·Î ÇÏ¿´°í ´ÙÀ½³¯ °í¿ÀÌ Áö¼ÓµÇ¾î ´Ù½Ã ³»¿øÇÏ¿´°í ¼ö¾×Ä¡·á¸¸ ÇÏ°í °æ°ú °üÂûÇÏ¿´½À´Ï´Ù. 2ÀÏÈÄ ´Ù½Ã ¿Ô´Âµ¥ °í¿ÀÌ Áö¼ÓµÇ°í ÀüüÀûÀÎ º¹Åë ¹× ±¸¿ª°¨À» È£¼ÒÇÏ¿´½À´Ï´Ù. À§³»½Ã°æ °Ë»ç¸¦ ÇÏ¿´°í À§±Ë¾çÀÌ °üÂûµÇ¾úÀ¸³ª ¹ß¿ µîÀÇ Áõ»óÀÌ À§±Ë¾çÀ¸·Î ¼³¸íµÇÁö ¾Ê¾Æ º¹ºÎ ÃÊÀ½ÆÄ °Ë»ç¸¦ ÇÏ¿´°í Liver S8¿¡ 3.5*4cm Å©±âÀÇ liver abscess°¡ °üÂûµÇ¾î »ó±ÞÀÇ·á±â°üÀ¸·Î ÀÇ·ÚÇÏ¿´½À´Ï´Ù. Áø´ÜÀÌ Áö¿¬µÇ¾î ȯÀÚ¿¡°Ô ¿ø¸ÁÀ» µé¾ú´ø ÄÉÀ̽º Áß ÇϳªÀÔ´Ï´Ù.
43¼¼ ¿©ÀÚ È¯ÀÚ È¯ÀÚÀÔ´Ï´Ù. ¿, ¿ÀÇÑ, ±¸¿ª°¨, »óº¹ºÎ ºÒÆí°¨À¸·Î ³»¿øÇÑ È¯ÀÚÀÔ´Ï´Ù. AGE·Î Áø´ÜÇÏ°í 3ÀÏÈÄ °æ°ú¸¦ º¸¾Ò´Âµ¥ Áõ»óÀÇ È£ÀüÀÌ ¾ø°í ¹Ì¿ÀÌ Áö¼ÓµÇ°í ÀÖ¾ú½À´Ï´Ù. 2¹ø° ¹æ¹®¿¡¼µµ ƯÀÌ ¼Ò°ßÀÌ ¾ø¾î Ãß°¡ ó¹æÀ» ÇÏ°í °æ°ú¸¦ º¸±â·Î Çߴµ¥ ´ÙÀ½³¯ ÇÏ·ç Á¾ÀÏ Áö¼ÓµÇ´Â µþ±¹Áú·Î ´Ù½Ã ³»¿øÇÏ¿´½À´Ï´Ù. º¹ºÎ ÃÊÀ½ÆÄ °Ë»ç¸¦ ÇÏ¿´´õ´Ï diffuse GB wall thickeningÀÌ °üÂûµÇ¾î ȯÀÚ¿¡°Ô ¼Òº¯»ö±ò¿¡ ´ëÇØ ¹°¾îºÃ´õ´Ï ¸Å¿ì ÁøÇØÁ³´Ù°í ÇÏ¿´½À´Ï´Ù. AÇü °£¿° ÀǽÉÀ¸·Î ±Ùó ´ëÇк´¿øÀ¸·Î ÀÇ·ÚÇß´ø ȯÀÚÀÔ´Ï´Ù. Áø´ÜÀ» »¡¸® ¸øÇصå·Á ¹Ì¾ÈÇß´ø Áõ·Ê¿´½À´Ï´Ù. ¿, º¹ÅëÀ» µ¿¹ÝÇϴµ¥ µþ²ÚÁúÀ» ÇÑ´Ù¸é ¹Ýµå½Ã AÇü °£¿°À» ÀǽÉÇϽʽÿÀ. Hepatitis°¡ diaphragmÀ» ÀÚ±ØÇϱ⠶§¹®ÀÔ´Ï´Ù.
[2015-11-5. ÀÌÁØÇà ´äÀå]
¹«Ã´ Èï¹Ì·Ó½À´Ï´Ù. Àúµµ ³»°úÀÇ»çÀÌÁö¸¸ hiccup°ú hepatitis A¸¦ ¿¬°áÇÏ´Â ¹ýÀ» ¸ô¶ú½À´Ï´Ù. °£´ÜÈ÷ WebMD¸¦ ã¾Æº¸¾Ò´Âµ¥ ¾Æ·¡¿Í °°Àº ºÎºÐÀÌ ÀÖ´õ±º¿ä. °¨»çÇÕ´Ï´Ù. ¿äÁòÀº ÈĹèµé¿¡°Ô ¸¹ÀÌ ¹è¿ì°í ÀÖ½À´Ï´Ù.
A hiccup is an involuntary spasmodic contraction of the muscle at the base of the lungs (diaphragm) followed by the rapid closure of the vocal cords. Usually, hiccups last for a few hours or, occasionally, a day or two. However, chronic hiccups are ones that continue for an extended period of time. Episodes that last for more than two days and less than a month are sometimes called persistent hiccups. On rare occasions, hiccups persist even longer than a month or recur frequently over an extended period of time. The longest recorded episode of these chronic hiccups lasted 60 years.
Sometimes, although not always, hiccups that persist may indicate the presence of another medical problem. Some illnesses for which continuing hiccups may be a symptom include: pleurisy of the diaphragm, pneumonia, uremia, alcoholism, disorders of the stomach or esophagus, and bowel diseases. Hiccups may also be associated with pancreatitis, pregnancy, bladder irritation, liver cancer or hepatitis. Surgery, tumors, and lesions may also cause persistent hiccups.
°³¿øÇÏ°í AGE·Î Áø´ÜÇÏ°í °æ°ú °üÂûÁß¿¡ perforated appendicitis·Î ¼ö¼úÇÏ°í ȯÀÚ³ª º¸È£ÀÚ¿¡°Ô ¿¬¶ô¿Í¼ ¿ø¸ÁÀ» µé¾ú´ø °æ¿ì°¡ µÎ¹ø ÀÖ¾ú½À´Ï´Ù. ¿¬¶ôÀÌ ¿Í¼ ¾Ë°Ô µÈ °æ¿ì°¡ µÑÀÌÁö ¿¬¶ô¿ÀÁö ¾ÊÀº ȯÀÚ±îÁö ÇÕÄ¡¸é ´õ ¸¹À» °ÍÀÔ´Ï´Ù.
70´ë ¿©ÀÚ È¯ÀÚ¿´½À´Ï´Ù. ±¹¼ÒÀûÀÌ ¾Æ´Ñ Àü¹ÝÀûÀÎ º¹Åë ¹× ¼Ó´õºÎ·èÇÔ, üÇÑ ´À³¦ µîÀ¸·Î ³»¿øÇÏ¿´´Âµ¥ ¿ìÇϺ¹ºÎ ÅëÁõÀ̳ª ¾ÐÅë, ¹Ý¹ß¾ÐÅë µîÀº ¾ø¾ú½À´Ï´Ù. ¿µµ ¾ø¾úÀ¸³ª ƯÀÌÇÑ »çÇ×Àº ÇÑ 1ÁÖÀÏ° ¹ã¸¶´Ù ½ÄÀº¶¡ÀÌ ³´Ù´Â °ÍÀ̾ú½À´Ï´Ù. ÁøÂû¼Ò°ß»ó ƯÀÌ »çÇ×ÀÌ ¾ø¾î AGE¿¡ ÁØÇØ Áõ»óÁ¶Àý¾à ó¹æÈÄ °æ°ú °üÂûÇÏ¿´´Âµ¥ 3ÀÏÈÄ ÀüÈ°¡ ¿Í¼ º¹ÅëÀÌ ´õ ½ÉÇØÁ® ÀÀ±Þ½Ç ¹æ¹®ÈÄ perforated appendicitis·Î ¼ö¼úÇÏ¿´´Ù¸ç ¿ø¸ÁÀ» µé¾ú½À´Ï´Ù.
10´ë ÈÄ¹Ý ³²ÀÚ °íµîÇлýÀ̾ú½À´Ï´Ù. ¿/±ÙÀ°Åë/±¸Åä/º¹ÅëÀ¸·Î ³»¿øÇÏ¿´°í Àü¹ÝÀûÀÎ º¹ºÎ ¾ÐÅëÀÌ ÀÖ¾úÁö¸¸ ºÐ¸í ¿ìÇϺ¹ºÎ ¾ÐÅë ¹× ¹Ý¹ßÅëÀÌ ¾ø¾ú½À´Ï´Ù. AGE·Î »ý°¢ÇÏ°í º¸Á¸Àû Ä¡·á ¹× ¼ö¾×Ä¡·áÇÏ°í °æ°ú °üÂû Çϱâ·Î ÇÏ¿´À¸³ª ´ÙÀ½ ³¯¿¡µµ °í¿¿¡ º¹ÅëÀÌ Áö¼ÓµÇ¾î ³»¿øÇÏ¿´½À´Ï´Ù. ¾Æ¿¹ Ãæ¼ö¿°À» ÀǽÉÇÏ°í ¸é¹ÐÇÑ ÀÌÇÐÀû °Ë»ç¸¦ ÇÏ¿´À¸³ª ¿ìÇϺ¹ºÎ ¾ÐÅëÀÌ ÀüÇô ¾ø°í ¿ÀÈ÷·Á ¼³»çµµ ÀÖ´Ù°í ÇÏ¿© Ãæ¼ö¿° °¡´É¼ºÀÌ ¶³¾îÁø´Ù°í ±îÁö ¼³¸íÇÏ¿´½À´Ï´Ù. ´ÙÀ½ ³¯ ´Ù½Ã Áõ»ó ¾ÇÈ·Î ³»¿øÇÏ¿´°í Áø´ÜÀÌ ¸ðÈ£Çؼ ´ëÇк´¿ø ÀÀ±Þ½Ç·Î ÀÇ·ÚÇß¾ú´Âµ¥ perforated appendicitis·Î Áø´Ü¹Þ°í ¼ö¼úÇÏ¿´½À´Ï´Ù. º¸È£ÀڷκÎÅÍ ¿ÀÁøÀ̶ó°í ¿ø¸ÁÀ» µé¾ú½À´Ï´Ù.
Ãæ¼ö¿° ÀǽÉÀ¸·Î ÀÀ±Þ½Ç·Î º¸³½ ÈÄ Ãæ¼ö¿°ÀÌ ¾Æ´Ñ °ÍÀ¸·Î Áø´ÜµÇ¾î À߸ø Áø´ÜÇÏ¿© °Ë»çºñ ¸¹ÀÌ ½è´Ù°í ºÒÆòÇÏ´Â ÀüÈ´Â ÈξÀ ´õ ¸¹ÀÌ ¹Þ¾Æ ºÃ½À´Ï´Ù. °³¿ø°¡¿¡¼ appendicitis´Â ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ±×¾ß¸»·Î õÀÇ ¾ó±¼À» °¡Áö°í ÀÖ°í Áø´ÜÀÌ ¾Ö¸ÅÇÑ °æ¿ì°¡ ¸¹°í ¿ÀÁøÇϰųª ³õÃÆÀ» °æ¿ì medicolegal problemÀ¸·Î ³Ñ¾î°¡±â ½±±â ¶§¹®ÀÔ´Ï´Ù. ±×·¸´Ù°í ¹æ¾îÁø·á¸¦ ÇÏ´À¶ó º¹ÅëÀ¸·Î ¿À´Â ¸ðµç ȯÀڵ鿡°Ô °úµµÇÑ °Ë»ç¸¦ ±ÇÇϰųª Ãæ¼ö¿°¿¡ ´ëÇÑ Áö³ªÄ£ °ÌÁֱ⠶ÇÇÑ ¿Ã¹Ù¸¥ ÀÚ¼¼´Â ¾Æ´Ò °ÍÀÔ´Ï´Ù.
Ãæ¼ö¿°ÀÌ º»°ÝÀûÀ¸·Î ÁøÇàÇÑ °æ¿ì¿¡´Â ÀüÇüÀûÀÎ Áõ»ó¿¡ ¿ìÇϺ¹ºÎ ¾ÐÅë, ¹Ý¹ß¾ÐÅëÀÌ ÀÖ´Â °æ¿ì´Â ½±Áö¸¸ Ãæ¼ö¿° Ãʱ⳪ Ãæ¼ö°¡ õ°øÀÌ µÈ °æ¿ì´Â ¿ìÇϺ¹ºÎ ÅëÁõ ¹× ÀüÇüÀûÀÎ ÁøÂû¼Ò°ßÀÌ ¼Ò½ÇµÇ¾î ¹ö¸®´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. Ç÷¾×°Ë»ç°¡ ¹Ù·Î °¡´ÉÇÏ´Ù¸é Ãß°¡ÀûÀÎ Á¤º¸¸¦ ¾òÀ» ¼ö ÀÖ°ÚÁö¸¸ ÀÓ»óº´¸®»ç°¡ »ó±ÙÇÏ´Â Á¤µµÀÇ °³ÀÎ ÀÇ¿øÀº ±Ô¸ð°¡ Å« ÀϺÎÀÔ´Ï´Ù. º¹ºÎ ÃÊÀ½ÆÄ·Î Ãæ¼ö¿° Áø´Ü¿¡ µµ¿òÀ» ¹ÞÀ» ¼ö ÀÖ°ÚÁö¸¸ ºñ¿ëÀ» µé¿© °Ë»ç¸¦ Çߴµ¥ ¾Ö¸ÅÇÑ °á°ú°¡ ³ª¿À°Å³ª Ãæ¼ö°¡ º¸ÀÌÁö ¾ÊÀ¸¸é ȯÀÚ³ª º¸È£ÀÚ°¡ ³³µæÇÏÁö ¾ÊÀ» »Ó´õ·¯ ÇÏÁö ¾ÊÀº °Í¸¸ ¸øÇÏ°Ô µË´Ï´Ù.
¿Õµµ´Â ¾ø´Â°Í °°½À´Ï´Ù. ¿½ÉÈ÷ ÁøÂûÇÏ°í ¿½ÉÈ÷ ¼³¸íÇؼ ȯÀÚ¿ÍÀÇ ¶ó»Ç¸¦ Àß Çü¼ºÇÏ´Â ¼ö ¹Û¿¡ ¾ø´Â °Í °°½À´Ï´Ù. ¾Õ¿¡¼ ¾ð±ÞÇÑ liver abscess, hepatitis A, perforated appendicitisÀÇ °æ¿ì °øÅëµÈ Á¡Àº 48½Ã°£-72½Ã°£ µ¿¾È ¿ÀÌ ³µ´Ù´Â °ÍÀÔ´Ï´Ù. °í·É ȯÀÚ´Â ¿ÀÌ ¾øÀ» ¼ö ÀÖÀ¸¹Ç·Î ´õ Á¶½ÉÇØ¾ß ÇÕ´Ï´Ù. ´ë°³ÀÇ AGE´Â 24-48½Ã°£ ¾È¿¡ ¿ÀÌ ¶³¾îÁö¹Ç·Î 3ÀÏÀÌ»ó ¿ÀÌ ³ª´Â ºñÁ¤ÇüÀûÀÎ º¹ÅëÀº Ç÷¾×°Ë»ç ¹× º¹ºÎ CT °Ë»ç¸¦ ±ÇÀ¯ÇØ¾ß ÇÑ´Ù°í »ý°¢ÇÕ´Ï´Ù.
³»°úÀÇ»ç·Î °³¿øÇÏ¿© °¡Àå ¸¹ÀÌ º¸°Ô µÇ´Â ȯÀÚ°¡ º¹Åë ȯÀÚÀÔ´Ï´Ù. °¨±âÀÇ °æ¿ì À̺ñÀÎÈÄ°ú, °¡Á¤ÀÇÇаú, ³»°ú·Î ȯÀÚ°¡ ³ª´µÁö¸¸ º¹ÅëÀº °ÅÀÇ ´ëºÎºÐ ³»°ú·Î ¿É´Ï´Ù. º¹Åë°ú °ü·ÃµÈ °ú´Â ³»°ú ¿Ü¿¡µµ »êºÎÀΰú, ºñ´¢±â°ú, ¿Ü°ú µîÀÌ ÀÖÁö¸¸ ÀÌ·± ȯÀڵ鵵 ÀÏ´Ü ³»°ú¿¡¼ Áø´Ü °úÁ¤À» °ÅÄ£ ÈÄ Àü¹®°ú·Î ÀǷڵǴ °æ¿ì°¡ ¸¹½À´Ï´Ù. ±×·¡¼ ³»°ú °³¿øÀÇ´Â º¹ÅëÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â ¸ðµç ÁúȯÀ» °æÇèÇÏ°Ô µË´Ï´Ù. ¼Òȼº±Ë¾ç, Àå¿°, ÃéÀå¿°, ´ã³¶¿°, ´ãµµ¿°, Ãæ¼ö¿°, °Ô½Ç¿° µîÀÇ ¼Òȱâ Áúȯ »Ó ¾Æ´Ï¶ó ¿ä·Î°á¼®, ½Å¿ì¿°, ÀÚ±Ã¿Ü ÀÓ½Å, ³¼Ò¿°Àü, °ñ¹Ý¿°±îÁö ¸ðµç º¹Åë ȯÀÚ¸¦ °ÞÀ» ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù.
¾Ö¸ÅÇÑ Áõ»óÀ» È£¼ÒÇÏ´Â °æ¿ìµµ ¸¹½À´Ï´Ù. ÁַΠüÇÑ °Í °°´Ù, ¹è°¡ ´õºÎ·èÇÏ°í ¼ÒÈ°¡ ¾ÈµÈ´Ù, ¾îµòÁö ¸ð¸£°Ô ºÒÆíÇÏ´Ù µîµîÀÔ´Ï´Ù. ±×·¯³ª ÁÖ·Î ¹®Áø°ú ÁøÂû·Î ÁÖ·Î Áø´ÜÇÏ´Â °ÍÀÌ ³»°ú °³¿øÀÇÀÇ ³ª¸§ Ư¼öÇÑ »óȲÀÔ´Ï´Ù. ¿äÁò ÀÇ´ë»ý ¹× Àü°øÀÇ ±³À°Àº ³Ê¹« ÃÖ÷´Ü Áø´Ü±â±âÀÇ µµ¿ò¿¡ ¿À¸®¿£Æ¼µå µÈ °æÇâÀÌ ÀÖ½À´Ï´Ù. Á¦°¡ ¼ö·Ã¹ÞÀ» ¶§µµ ±×·¯ÇÏ¿´½À´Ï´Ù. ±×³ª¸¶ ¿Ü·¡ ȯÀÚ¸¦ º¼ ¼ö ÀÖ´Â ±âÃÊÀÎ ÀÀ±Þ½Ç Á¶Â÷ º¹ÅëÀ» º¹ºÎ CT·Î ½±°Ô ÇØ°áÇÏ´Â ½Ã½ºÅÛÀº ÀÚ½ÅÀÇ ÀÓ»ó °æÇèÀ» ½×´Âµ¥ º°·Î µµ¿òÀÌ ¾ÈµÉ ¼ö ÀÖ½À´Ï´Ù. ³»°ú Àü°øÀÇ ±³À° ¶§ º¹ÅëÀÇ Áø´ÜÇп¡ ´ëÇÑ Æ÷°ýÀûÀÌ°í ¼¼¹ÐÇÑ ±³À° ¹× ÇнÀÀÌ ÇÊ¿äÇÏ´Ù°í »ý°¢µË´Ï´Ù.
Æø³ÐÀº µ¶ÀÚÃþÀ» °¡Áö°í ÀÖ´Â ÀÌÁØÇà ±³¼ö´ÔÀÇ EndoTODAY¸¦ ÅëÇØ ÈĹè´Ôµé²² µå¸®°í ½ÍÀº ¸»¾¸ÀÌ ÀÖ½À´Ï´Ù. Àü°øÀÇ È¤Àº ÀüÀÓÀÇ ÈĹè´ÔµéÀº ÃÖ÷´Ü Áø´Ü modality·Î ¾òÀº Áø´Ü¿¡ ¸¸Á·ÇÏÁö ¸¶½Ê½Ã¿À. ´Ù½Ã Çѹø ¹®ÁøÇÏ°í ÁøÂûÇÏ¿© ÀÚ½ÅÀÇ ¼ÒÁßÇÑ ÀÓ»ó °æÇèÀ¸·Î ¸¸µå´Â ³ë·ÂÀ» °ÔÀ»¸®ÇÏÁö ¸¶½Ê½Ã¿À. Àü°øÀdzª ÀüÀÓÀÇ ¶§ ±×·¸°Ô ÇÏÁö ¸øÇß´ø ¼±¹è·Î¼ Ãæ¾ðÇØ µå¸®°í ½Í½À´Ï´Ù.
ÀÇÇÐÀÇ ²ÉÀÎ ³»°ú°¡ ¾î·Æ´Ù´Â À̾߱Ⱑ µé¸³´Ï´Ù. Àü°øÀÇ Áö¿øÀÚµµ °¨¼ÒÇÏ¿© Áö¹æº´¿ø¿¡¼´Â Á¤¿øÀ» ä¿ìÁö ¸øÇÏ´Â °æ¿ì°¡ ¸¹´Ù°í µé¾ú½À´Ï´Ù. ¿Ö°îµÈ ÀÇ·á ȯ°æ¿¡¼ ³»°ú °³¿ø°¡°¡ ¾î·Æ±â ¶§¹®ÀÏ °ÍÀÔ´Ï´Ù. Àú¼ö°¡·Î ÀÎÇØ º´¿øÀ» À¯ÁöÇϱâ À§Çؼ´Â ÇÏ·ç¿¡ 100¸í¿¡ À°¹ÚÇϴ ȯÀÚ¸¦ ºÁ¾ßÇÏ´Â ºñÁ¤»ó ÀÇ·á½Ã½ºÅÛ¿¡¼ ¸ðµç ȯÀÚ¸¦ ¿ÏÀü ¹«°áÇÏ°Ô º¸´Â °ÍÀº óÀ½ºÎÅÍ ºÒ°¡´ÉÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¡¼ Àú´Â ÀÌÁØÇà ±³¼ö´ÔÀÇ ¿ø°í ºÎŹÀ» ¹Þ°í °æÇèÀÇ °øÀ¯°¡ ½Ç¼ö¸¦ ÁÙÀÏ ¼ö ÀÖ´Â ±âȸ°¡ µÉ °ÍÀ̶ó°í »ý°¢Çß½À´Ï´Ù.
¸¶Áö¸·À¸·Î ¾ó¸¶ ¾ÈµÇ´Â °³¿ø»ýÈ°À» ªÀº ½Ã°£À̳ª¸¶ µ¹¾Æº¼ ¼ö ÀÖ´Â ±âȸ¸¦ ÁֽŠÀÌÁØÇà ±³¼ö´Ô²² ±íÀº °¨»çÀÇ Àλ縦 µå¸³´Ï´Ù.
Á¦ÀÚ XXX ¿Ã¸²
ȯÀÚ ÇѸí ÇѸíÀÇ »ç¿¬ÀÌ ¸ðµÎ °¡½¿À» ¿ï¸³´Ï´Ù. Á¤¼º²¯ Áø·áÇߴµ¥ ¿ÀÁøÇß´Ù°í ¿ø¸Áµè´Â °æ¿ì´Â ³²ÀÇ ÀÏ °°Áö ¾Ê½À´Ï´Ù.
ÈĹèµéÀ» À§ÇÏ¿© ±ä½Ã°£ ÀڷḦ Á¤¸®ÇØ Áּż °¨»çÇÕ´Ï´Ù. ÇÔ²² °øºÎÇÏ¿© ½Ç·ÂÀ¸·Î ȯÀÚ¿¡°Ô ºÀ»çÇÏ´Â ÁÁÀº Àǻ簡 µË½Ã´Ù. ¾ÕÀ¸·Îµµ Á¾Á¾ Áõ·Ê º¸³»Áֽñ⠹ٶø´Ï´Ù.
ÀÏ¿øµ¿¿¡¼ ÀÌÁØÇà.
¿ø°í¸¦ º¸³»ÁֽŠ¼±»ý´Ô²² ±³Á¤À» ºÎŹÇß´õ´Ï »ó¼¼ÇÑ °ËÅä¿Í ÇÔ²² ¾Æ·¡¿Í °°Àº ´äÀåÀ» Áּ̽À´Ï´Ù. ´õ¿í °¨»çÇÑ ÀÏÀÔ´Ï´Ù.
[2015-11-6. ¾Öµ¶ÀÚ ´äÀå]
±³¼ö´Ô! XXXÀÔ´Ï´Ù.
¸ÕÀú ÀüÈÁÖ¼ÌÀ» ¶§ ¾Õ¿¡ ȯÀÚ°¡ ÀÖ¾î Á¦´ë·Î ÀüÈÀÀ´ë¸¦ ¸øÇص帰°Í °°¾Æ ¸¶À½ÀÌ ¾²¿´¾ú½À´Ï´Ù. Á¦ ¿ø°íÀÇ Çй®Àû ¼öÁØÀÌ ³·¾Æ¼ °ÆÁ¤Çß¾ú´Âµ¥ ±³¼ö´Ô²²¼ ³Ê¹« Àç¹ÌÀÖ°Ô ÀоîÁ̴ּٰí Çؼ Âü ±â»¼½À´Ï´Ù.
ÀÌ°Ç °³ÀÎÀûÀÎ °í¹ÎÀä. °³¿øÇÏ°í ³ª¸é »ç½Ç ´ëÀΰü°è°¡ ¸Å¿ì Á¼¾ÆÁö°í Áø·áÇÏ´Â ÀÏÀ» »©¸é ÇÏ·ç ÇÏ·ç°¡ ³Ê¹« ·çƾó·³ µ¹¾Æ°¡±â¶§¹®¿¡ ¼º°Ýµµ ³»¼ºÀûÀ¸·Î ¿òÃ÷·Áµé°í ¼Ò½ÉÇØÁö´Â °Í °°½À´Ï´Ù. ½ÇÁ¦·Î ¿ì¿ïÁõÀ» °¡Áö°í ÀÖ´Â °³¿øÀǵ鵵 ¸¹°í ÁÖÀ§¿¡´Â ¿ì¿ïÁõ¾àÀ» ¸Ô°í °è½Å ¿øÀå´Ôµéµµ ¸¹½À´Ï´Ù. Á¼Àº Áø·á½Ç ¾È¿¡¼¸¸ ÇÏ·çÀÇ ´ëºÎºÐÀ» º¸³»´Âµ¥´Ù Àΰ£°ü°è°¡ Çù¼ÒÇØÁö´Ùº¸´Ï ¾îµð¿¡ °í¹ÎÀ̳ª ½ºÆ®·¹½º¸¦ º¥Æ¿·¹ÀÌ¼Ç ÇÒ °÷µµ º°·Î ¾ø±â ¶§¹®ÀÏ °ÍÀÔ´Ï´Ù.
¹°·Ð Àú´Â ±×Á¤µµ´Â ¾Æ´Õ´Ï´Ù¸¸ ±³¼ö´Ô²² ³»½Ã°æÀ» Á÷Á¢ ¹è¿î Á¦Àڷμ ±³¼ö´ÔÀÇ ¿£µµÅõµ¥À̸¦ º¸±â¸¸ ÇßÁö ¾×ƼºêÇÏ°Ô Áú¹®À» Çϰųª ÄÚ¸àÆ®¸¦ Çϰųª µîÀÇ ¾×ƼºñƼ°¡ ¾ø¾î ÇÑÆíÀ¸·Î´Â Á˼ÛÇϱ⵵ Çß¾ú½À´Ï´Ù. À̹øÀ» °è±â·Î ±×·± ¿òÃ÷·¯µë°ú ¼Ò½ÉÇØÁüÀ» Å»ÇÇÇغ¸·Á°í ÇÕ´Ï´Ù. ÀÌ·± °è±â¸¦ ÁֽŠ±³¼ö´Ô²² ´Ù½Ã Çѹø °¨»çµå¸³´Ï´Ù.
±³¼ö´Ô²²¼ ±³Á¤À» ºÁÁֽŠ¿ø°í´Â ÈξÀ º¸±â ÁÁ°í ¼¼·ÃµÇ¾îÁø°Í °°¾Æ¼ ³Ê¹« ¸¸Á·½º·´½À´Ï´Ù. ±³¼ö´Ô °¨»çÇÕ´Ï´Ù. ´ÙÀ½¿¡ ½Ã°£µÇ½Ã¸é Á¦°¡ ½Ä»ç¶óµµ Çѹø ´ëÁ¢Çص帮°í ½Í½À´Ï´Ù. ¿äÁò ÇÖÇÏ´Ù´Â XX·Î Ȥ½Ã ¿À½Ã°Ô µÇ¸é ²À ¿¬¶ô ÁֽʽÿÀ.
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.